Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Authors
Keywords
-
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 29, Issue 3, Pages 1579-1591
Publisher
Springer Science and Business Media LLC
Online
2021-11-01
DOI
10.1245/s10434-021-10991-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer
- (2021) Zhiliang Chen et al. MEDICINE
- Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis
- (2021) Aileen Deng et al. EUROPEAN JOURNAL OF CANCER
- Sustained Carbohydrate Antigen 19‐9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival
- (2020) J. Bart Rose et al. ONCOLOGIST
- Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy
- (2020) Ryan K. Schmocker et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival
- (2020) Ananya Panda et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
- (2019) Mark J. Truty et al. ANNALS OF SURGERY
- Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
- (2019) Ayhan Ulusakarya et al. MEDICINE
- Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX
- (2019) Timothy J. Vreeland et al. PANCREAS
- Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
- (2018) Jin He et al. ANNALS OF SURGERY
- Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection
- (2018) May C. Tee et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
- (2017) Claudio Bassi et al. SURGERY
- Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
- (2017) Theodoros Michelakos et al. ANNALS OF SURGERY
- FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
- (2015) Eran Sadot et al. ANNALS OF SURGICAL ONCOLOGY
- Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
- (2014) J. Bart Rose et al. ANNALS OF SURGICAL ONCOLOGY
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
- (2013) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic Ductal Adenocarcinoma
- (2012) Ioannis T. Konstantinidis et al. ANNALS OF SURGERY
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
- (2012) Hiroshi Haeno et al. CELL
- Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis
- (2011) Qing Zhao et al. Annals of Diagnostic Pathology
- Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
- (2011) Yun Shin Chun et al. ANNALS OF SURGICAL ONCOLOGY
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
- (2011) Deyali Chatterjee et al. CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Redefining resection margin status in pancreatic cancer
- (2010) Caroline S. Verbeke et al. HPB
- The Clavien-Dindo Classification of Surgical Complications
- (2009) Pierre A. Clavien et al. ANNALS OF SURGERY
- Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin
- (2009) Fiona Campbell et al. HISTOPATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started